Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related m
Generic drugmaker Accord Healthcare has announced a £50 million ($65 million) investment in the UK that will include the construction of a new medicines manufacturing facility.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.
With artificial intelligence technologies for healthcare on the rise, UK health technology assessment (HTA) agency NICE has published an economic evaluation standard that it says will help